Terns Pharmaceuticals Stock Today
| TERN Stock | USD 6.01 1.01 14.39% |
Performance0 of 100
| Odds Of DistressOver 55
|
Terns Pharmaceuticals is selling at 6.01 as of the 1st of June 2024; that is -14.39 percent down since the beginning of the trading day. The stock's open price was 7.02. Terns Pharmaceuticals has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Terns Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of May 2024 and ending today, the 1st of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. The company has 64.68 M outstanding shares of which 2.23 M shares are at this time shorted by private and institutional investors with about 2.94 trading days to cover. More on Terns Pharmaceuticals
Moving together with Terns Stock
| 0.8 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Terns Stock
| 0.54 | SGHT | Sight Sciences Trending | PairCorr |
| 0.41 | KIDS | Orthopediatrics Corp | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Terns Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Terns Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Terns Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Terns Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Terns Pharmaceuticals' managers, analysts, and investors.
Environmental | Governance | Social |
| CEO Director | Amy MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Israel Wall Street (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Israel Wall Street, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Terns Pharmaceuticals report their recommendations after researching Terns Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Terns Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Terns Pharmaceuticals. The Terns consensus assessment is calculated by taking the average forecast from all of the analysts covering Terns Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Terns Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Terns Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in July. Financial strength of Terns Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terns Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Terns Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Terns Pharmaceuticals' financial leverage. It provides some insight into what part of Terns Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terns Pharmaceuticals (TERN) is traded on NASDAQ Exchange in USA. It is located in 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 and employs 66 people. Terns Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 454.03 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Terns Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Terns Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Terns Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 64.68 M outstanding shares of which 2.23 M shares are at this time shorted by private and institutional investors with about 2.94 trading days to cover.
Terns Pharmaceuticals currently holds about 139.81 M in cash with (67.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51.
Check Terns Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationTerns Pharmaceuticals maintains a total of 64.68 Million outstanding shares. The majority of Terns Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Terns Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Terns Pharmaceuticals. Please pay attention to any change in the institutional holdings of Terns Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Terns Ownership Details
Terns Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Terns Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Terns Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Terns Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Suvretta Capital Management, Llc | 2024-03-31 | 1.4 M | |
| Great Point Partners Llc | 2024-03-31 | 1.3 M | |
| Driehaus Capital Management Llc | 2024-03-31 | 1.1 M | |
| State Street Corporation | 2023-12-31 | 886.9 K | |
| Adage Capital Partners Gp Llc | 2024-03-31 | 850 K | |
| Geode Capital Management, Llc | 2023-12-31 | 840.5 K | |
| Decheng Capital Llc | 2023-12-31 | 714.3 K | |
| Octagon Capital Advisors Lp | 2024-03-31 | 625 K | |
| Longwood Capital Partners Llc | 2024-03-31 | 465.1 K | |
| Orbimed Advisors, Llc | 2024-03-31 | 7.6 M | |
| Vivo Capital, Llc | 2024-03-31 | 6.7 M |
Terns Pharmaceuticals Historical Income Statement
Terns Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Terns's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Terns Pharmaceuticals revenue and expense. Terns Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 1st of June 2024, Net Interest Income is likely to grow to about 13.5 M, while Depreciation And Amortization is likely to drop about 564.5 K. View More FundamentalsTerns Stock Against Markets
Picking the right benchmark for Terns Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Terns Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Terns Pharmaceuticals is critical whether you are bullish or bearish towards Terns Pharmaceuticals at a given time. Please also check how Terns Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Terns Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Terns Pharmaceuticals Corporate Management
Elected by the shareholders, the Terns Pharmaceuticals' board of directors comprises two types of representatives: Terns Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Terns. The board's role is to monitor Terns Pharmaceuticals' management team and ensure that shareholders' interests are well served. Terns Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Terns Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weidong Zhong | CoFounder Officer | Profile | |
| Jeffrey Jasper | Senior Research | Profile | |
| Mark Vignola | CFO Treasurer | Profile | |
| Senthil Sundaram | CEO Director | Profile |
How to buy Terns Stock?
Before investing in Terns Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Terns Pharmaceuticals. To buy Terns Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Terns Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Terns Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Terns Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Terns Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Terns Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Terns Stock please use our How to Invest in Terns Pharmaceuticals guide.
Already Invested in Terns Pharmaceuticals?
The danger of trading Terns Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Terns Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Terns Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Terns Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Terns Stock analysis
When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.035 | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.